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Abstract
Background: Dabigatran is a newly commercialized drug that is replacing other anticoagulants in the prevention 
of venous thromboembolism, stroke and systemic arterial valve embolism. It acts directly on thrombin presenting 
in a dynamic and predictable way, which does not require monitoring these patients. Therefore, we consider the 
need to assess whether their use increases the risk of bleeding involved before any dental treatment. 
Material and Methods: We performed a systematic review with a bibliographic search in PubMed/Medline along 
with the Cochrane Library.  We excluded articles dealing with all anticoagulants other than dabigatran, and works 
about surgical treatments in anatomical locations other than the oral cavity. 
Results: We included a total of 13 papers of which 1 was a randomized clinical trial, 9 narrative literature reviews, 
1 case series, 2 clinical cases and 1 expert opinion. Because we did not obtain any properly designed clinical trials, 
we were unable to conduct a meta-analysis. 
Conclusions: Currently, there is no consensus on the procedure to be followed in patients taking dabigatran. 
However, all authors agree to treat each case individually in accordance to the risk of embolism, postoperative 
bleeding and renal function. Also, it is necessary to perform minimally invasive interventions, and take the appro-
priate local anti-hemolytic measures.
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Introduction
Atrial fibrillation is the most common cardiac arrhyth-
mia and a major cause of stroke in the United States and 
Europe. There is an estimated 2.2 million people suffer-
ing from this disease in the United States, and 4.5 mil-
lion in Europe. In patients with atrial fibrillation, 80% 
of heart attacks cause death or disability, and mortality 
per year reaches 50%. Vitamin K antagonists such as 
warfarin and acenocoumarol are very effective in pre-
venting strokes in patients with atrial fibrillation, and 
have been for many years; thus being the only drugs 
available for long-term anticoagulant therapy (1,2).
Warfarin and acenocoumarol exert its anticoagulant 
effects by reducing the levels of prothrombin and fac-
tor X; whereas heparin acts by binding to antithrombin 
and enhancing its ability to inhibit thrombin (Fig. 1). 
Fig. 1. Action levels of heparin, warfarin and dabigatran in the intrinsic and extrinsic 
coagulation pathways.
With regards to heparin, its main disadvantage is that it 
causes an indirect inhibition of thrombin unpredictable, 
as it is dependent on the availability of antithrombin. 
On the other hand, warfarin has its drawbacks with a 
narrow therapeutic window (the range in which a drug 
can be used without causing toxic or lethal effects on a 
living organism), the need to monitor the state of anti-
coagulation of a patient by controlling the International 
Normalized Ratio (INR), the numerous food and drug 
interactions, lack of direct action on coagulation pro-
teins and high start activity time and its removal (3-5). 
This large amount of disadvantages has been the basis 
for the development of new oral anticoagulants, which 
act directly inhibiting thrombin (1-6).
Dabigatran etexilate (Pradaxa, Boehringer Ingelheim 
Pharmaceuticals Inc., Ridgefield, CT), is a direct throm-
bin inhibitor, which was approved by the European 
Medicines Agency in 2008, and the Food and Drug Ad-
ministration (FDA) in October 2010 for the prevention 
of stroke and systemic embolism in patients with non-
valvular atrial fibrillation, as well as, for the prevention 
of venous thromboembolism after orthopedic surgery 
for total hip replacement or knee (4). 
However, patients taking warfarin or acenocoumarol 
have a pattern of reduction of the drug and a reference 
INR values that can be followed without the patient s´ 
risk of bleeding during dental procedures; yet there are 
no guidelines for managing patients taking dabigatran 
before dental procedures that can cause bleeding.
The aim of this paper is to perform a systematic review 
and meta-analysis summarizing if the use of dabigatran 
increases the risk of bleeding before dental procedures 
that involve bleeding, and if that risk is greater than that 
produced by conventional anticoagulants. Later, we will 
try to give a protocol of dental procedures that involve 
bleeding in patients treated with dabigatran.
Material and Methods
- Defining the questions:
To carry out this systematic review the questions we 
asked ourselves were as follows:
Does the use of dabigatran increases the risk of bleed-
ing when performing dental treatments which involve 
bleeding?; Is the risk of bleeding before such dental pro-
cedures involving bleeding greater than that produced 
by classic anticoagulant treatments such as heparin and 
warfarin?, and are there protocols for handling patients 
who take dabigatran prior to dental procedures that in-
volve bleeding?
- Search strategy:
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To carry out this systematic review we conducted a 
literature search in PubMed / Medline, and Cochrane 
Library databases using key words “dabigatran” AND 
“dentistry” and “dabigatran” AND “oral surgery”. Only 
papers with human subjects were selected. The titles and 
abstracts that resulted from the search were reviewed, 
and full-texts papers that were considered relevant to 
the review were read. Two authors (MMC and LRM) 
reviewed the papers selected independently. We com-
pared the lists, and when in disagreement, underwent 
discussion based on the inclusion and exclusion criteria. 
We then sought manually for additional papers review-
ing the references on selected articles.    
- Inclusion and exclusion criteria:
Inclusion criteria: 
All articles published in English, that discuss the risk of 
bleeding from dabigatran after dental treatment, were 
included. We included narrative reviews, case reports, 
case series, case-control studies, prospective studies, 
randomized clinical trials, and systematic reviews. We 
searched articles published in the last 10 years. The last 
electronic search was conducted in 15th October 2015. 
We selected only studies conducted in adult patients.
Exclusion criteria:
Studies were excluded if they were published in a lan-
guage other than English. Papers that assessed the 
bleeding caused by other anticoagulants (apart dabiga-
tran) were rejected. We did not include studies realized 
in animals. 
- Quality assessment
In the final selection of eligible studies, we assessed fea-
tures that could potentially bias following the recom-
mendations by Cochrane for assesing risk of bias. Criti-
cal appraisal was conducted by two reviewers (MMC 
and LRM) independently of each other. The reviewers 
met to discuss the results of their critical appraisal, if 
the two reviewers disagreed on the final critical apprais-
al and could not be resolved through discussion, a third 
reviewer (RLP) was required. 
Results
In figure 2, the search strategy and article selection is dis-
cussed. A total of 13 papers were included, 1 randomized 
clinical trial, 9 narrative literature reviews, 1 case series, 
2 clinical cases, and 1 expert opinion (Table 1).
We only found two papers that responded to the ques-
tion: Does the use of dabigatran increase the risk of 
bleeding in dental treatments that involve bleeding? 
The papers selected were two clinical cases, therefore 
of very poor methodological quality. Regarding the an-
swer to the question: Is the risk of bleeding before den-
tal procedures that involve bleeding in patients taking 
dabigatran greater than that produced by classical an-
ticoagulants (heparin and warfarin)? We could not find 
any papers that specifically answers that question; the 
study by Healy (7) in 2012 includes dental procedures 
among those evaluated, but does not specify subsequent 
bleeding complications specific to the type of surgery 
that the patients underwent. And yes, there are studies 
that answer the question, are there protocols for han-
dling patients (taking dabigatran) before dental proce-
dures that involve bleeding?  
All the studies reviewed provide different protocols 
for managing these patients, but none of these papers 
are based on results of methodological, well-designed 
studies, just mere opinions and recommendations from 
commercial brands and / or experts. 
Because we could not get properly designed clinical 
studies, we were unable to do a meta-analysis. We will 
describe in a summarized manner each of the selected 
papers.
Gómez-Moreno et al. (8) in their review in 2010, men-
tioned the lack of practical guidelines, as well as a lack 
of protocol to reduce drug dosage before dental pro-
cedures, and the importance of local hemostatic mea-
sures. Also, they emphasize among the advantages of 
dabigatran that it is a drug that does not interfere with 
antimicrobial antibiotics, most widely used in dentistry 
nowadays.
In the review by Little et al. (9) in 2012, in light of the 
revised articles, the authors conclude that patients treat-
ed with dabigatran may undergo invasive dental proce-
dures without altering the dose of the medication. The 
dentist should consult the patient’s physician to plan the 
procedure, and confirm whether the patient will con-
tinue with the same dose after surgery. To manage pos-
sible bleeding, local measures should be used. In cases 
requiring extensive oral surgery, it is important to con-
sult with the patient s´ physician to determine an action 
plan, in order to prevent thromboembolism, as well as, 
excessive bleeding. 
Firriolo and Hupp (10), in 2012 and Davis et al. (11), 
in 2013 also published reviews and recommendations 
based on other authors´ recommendations, as well as, 
the pharmacological properties of dabigatran; and they 
noted that it does not seem necessary to remove the 
drug prior to dental treatment, especially if local and 
adjuvant hemostatic measures are taken (suture, gelatin 
or cellulose sponges, tranexamic acid rinses at 4.8% for 
2-5 days). However, in cases where excessive bleeding 
or hemostatic problems are expected, dabigatran should 
be removed at least 24 hours before surgery or more 
depending on the risk of bleeding, renal function, and 
the presence of other conditions they could increase the 
bleeding (Table 2). Due to the anticoagulant effect, that 
quickly establishes, the drug should not be taken imme-
diately after surgery, instead once the clot is stabilized 
(24-48 hours after surgery). 
Weitz et al. (12) in 2012 published a case study of a pa-
tient taking dabigatran which presented bleeding com-
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plications. In the article, the authors do a systematic 
reviewed and include recommendations for minor sur-
gical procedures, such as no drug withdrawal in dental 
cleanings and extractions, and to do such procedures 
more than 10 hours after taking last dose of the drug. 
Van Diermen et al. (13) in 2013 conducted a review 
aimed at finding dental studies regarding the manage-
ment of anticoagulated patients, including those taking 
new anticoagulants; and to propose a patient manage-
ment guide for general practitioners. Regarding dabiga-
tran in patients subjected to simple dental treatments (up 
to 3 extractions, up to 3 implants, scaling and root plan-
ning, flap surgeries, alveoloplasties and apicoectomies), 
the authors made the following recommendations: To 
not stop taking dabigatran; Warn patients not to take 
their medication within 3 hours immediately after sur-
gery; and adopt local, pre and post-operative measures, 
such as minimizing surgical trauma, suture wounds, 
the use local hemostatics or apply pressure locally; also 
providing the patient with written instructions on how 
the post-operative measures should be, and the steps 
that the patient should take if he/she experiences bleed-
ing.  
Cohen et al. (5) in 2013 conducted a review and devel-
oped a small clinical management guide; they advised 
that the correct clinical care at the dental office should 
begin by writing a thorough medical history of the 
patient, collecting any previous episodes of excessive 
bleeding associated with anticoagulants or diseases of 
any kind. These authors suggest that basic oral surgery 
procedures such as few tooth extractions or localized 
periodontal surgery must be done at the first visit to 
assess the bleeding, followed by local hemostatic mea-
sures such as suture or gelatin sponges. If surgery is 
more complex or major bleeding is expected, one should 
consider withdrawing the drug for 48 hours, and after 
Fig. 2. Search strategy and selection diagram.
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consulting with the patient s´ physician. If the procedure 
post-operative healing is good, the patient could contin-
ue the medication the day after surgery. All these guide-
lines relate to a healthy patient without kidney or liver 
disease; in such cases, the drug should be withdrawn 
4-5 days depending on the physician s´ suggestions. 
Kerr et al. (14) published in 2013 a letter in which, as 
experts, proposed a management guide that suggests 
to not withdraw the medication, requiring the use of 
atraumatic extraction techniques, limiting the number 
of teeth extracted in the same procedure to 3-4, and lo-
cal hemostatic measures (sutures, local pressure and lo-
cal hemostatics). With this, they consider the treatment 
will be safe in a regular dental practice. It is also noted 
that such patients with recently placed stents, liver or 
kidney failure, alcohol problems, medicated with cyto-
toxic drugs and with clotting problems, should have the 
practitioner consult their physician before performing 
any dental procedures that cause bleeding.
Romond et al. (15) in 2013 published the case report 
of a patient who had eight dental extractions and pre-
prosthetic surgery (alveoloplasty and remodeling of the 
tuberosity in the maxilla) who was also taking dabiga-
tran. In this case, the patient withdrew dabigatran 24 
hours before the procedure, and surgery was performed 
under intravenous sedation and local hemostatic mea-
sures were taken, such as the use of local anesthesia 
with vasoconstrictor, gelatin sponges, suture and place-
ment of the immediate prosthesis. There was no exces-
sive bleeding or clotting problems in this case, making 
the healing process correct. The authors note that hav-
ing no agent to reverse the action of dabigatran is suf-
ficient reason for withdrawing the medication when the 
procedure is more invasive than 2-3 extractions. 
Breik et al. (16) in 2014 published a guide of recom-
mendations based on a series of cases of 5 patients 
who had single and multiple extractions. These authors 
recommended to not removing the dabigatran in pro-
Author Year Country of Publication Type of publication
Gómez-Moreno et al. (8) 2010 Spain Narrative review
Little et al. (9) 2012 United States Narrative review
Firriolo and Hupp (10) 2012 United States Narrative review
Weitz et al. (12) 2012 United States Clinical case and review
Healey et al. (7) 2012 United States Randomized clinical trial
Van Diermen et al. (13) 2013 United States Narrative review
Coehn et al. (5) 2013 United States Narrative review
Davis et al. (11) 2013 Canada Narrative review
Kerr et al. (14) 2013 United Kingdom Expert s´ opinion
Romond et al. (15) 2013 United States Clinical case
Breik et al. (16) 2014 Australia Case series
Curtin et al. (17) 2014 United Kingdom Narrative review
Sivolella et al. (18) 2015 Japan Narrative review
Table 1. Papers included in the systematic review.
Drug withdrawal time since last dose 
taken before surgery
Renal function
(creatinine clearance ml/min)
Dabigatran s´ 
half life (h)
Risk of standard 
bleeding
High risk of bleeding
>80 13 (11-22) 24h 2-4 days
>50 to <80 15 (12-34) 24h 2-4 days
>30 to <50 18 (13-23) >48h 4 days
<30 * 27 (22-35) 2-5 days >5 days
Table 2. Guide to discontinue use of dabigatran prior to surgical procedures.
* Dabigatran is contraindicated in these patients.
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cedures with less risk of bleeding, such as periodontal 
treatment, dental restorations with matrices, root canals 
or single tooth extractions. For the control of postop-
erative bleeding in simple uncomplicated extractions, 
local measures such as mechanical pressure, sutures 
and the use of local hemostatics are recommended. In 
cases where performing several extractions, the patient 
should be referred to his/her physician to assess the risk 
of withdrawing dabigatran 24 hours before surgery. If 
renal function is impaired, the withdrawal is assessed 
48 hours earlier. Activated partial thromboplastin time 
(aPTT) or thrombin time (TT) can be assessed previ-
ously to check the status of the patient anticoagulation. 
After the surgery, local hemostatic measures must take 
place and dabigatran can be resumed 24-48 hours later. 
Curtin et al. (17), in their review in 2014 also highlight 
the absence of clear clinical guidelines and recommend 
that dentists must know the existence of new anticoagu-
lants, both brand name and generic, consider possible 
drug interactions and to consult with a patient s´ physi-
cian before performing invasive treatments which may 
cause bleeding.
Sivolella et al. (18), published in 2015 a review sum-
marizing all prior publications about management of 
patients taking dabigatran and undergoing oral surgery 
procedures. They concluded that the management of 
these patients is essentially based on the average life 
of the drug and kidney condition of the patient. Fur-
thermore, they note that there are no clear guidelines to 
manage these patients, and clinical trials are needed to 
establish the protocols in the future.
Table 3 summarizes the pre and post-operative recom-
mendations published by all the different authors in this 
review with regards to dabigatran.
Discussion
Due to the fact that we have not found properly designed 
clinical studies, we will divide the discussion into two 
sections. The first section will summarize the drug s´ 
characteristics and how those can be an influence when 
carrying out dental treatments, and the second part, the 
management of anticoagulated patients with dabigatran 
and what to do with procedures that involve bleeding. 
- Dabigatran s´ characteristics
Dabigatran etexilate produces a dose-dependent prolon-
gation and nonlinear aPTT, while values such as TT, 
ecarin clotting time (ECT, test using the poison from 
the Echis carinatus snake) and INR rise in a linear fash-
ion and are dose-dependent. There is a close relation-
ship between plasma concentration of dabigatran, and 
the prolongation of blood clotting. Dabigatran acts di-
rectly on plasma thrombin, since it has been observed 
that the maximum effect on coagulation parameters oc-
curs simultaneously with the maximum concentration 
observed in plasma (3,10,13).
Dabigatran is administered as a prodrug, dabigatran 
etexilate, which has a rapid absorption via gastrointes-
tinal tract, and quickly becomes dabigatran; 20% of the 
drug is metabolized in the liver, and 80% is excreted 
primarily by the kidneys; thus having a half-life of about 
12 to 17 hours. Patients with a creatinine clearance <50 
ml/min may have a longer elimination and higher drug 
levels in plasma. In patients with severe renal failure 
(creatinine clearance <30 ml/min), dabigatran should be 
used with caution or contraindicated (3,4,9,11,15).
Dabigatran s´ peak effect occurs two hours after admin-
istration of the first dose, reaching a state of stability 3 
days after starting treatment with a regular dosage (e.g., 
150 mg twice daily). The effect duration is approxi-
mately 22 hours.
The advantage of this drug is that it does not need mo-
torization of the patient by means of coagulation tests 
(INR), thus far, introducing stable and predictable phar-
macodynamics 5,9. However, there is no coagulation 
measurement that could accurately predict the degree 
of anticoagulation in a patient medicated with dabiga-
tran, and there are no guidelines for routine monitoring 
of coagulation in these patients (3,5,13). 
Moreover, there is no consensus on what lab test is more 
effective to assess the clotting level in a patient, since 
measuring INR, a test familiar to physicians, does not 
display correctly the degree of coagulation of the pa-
tient (17,19). The most accessible laboratory tests to de-
termine the presence or absence of anticoagulant effect 
in patients taking dabigatran in case of emergencies are 
the aPTT and TT (15,19); however, the most appropriate 
and sensitive test to quantify the anticoagulant effect of 
this drug are ECT, dTT (diluted thrombin time) and the 
trial thrombin inhibitor Hemoclot ® (Hyphen BioMed, 
Neuville-sur-Oise, France) (10,18,19). 
In Erope, dabigatran has been approved for the pre-
vention of venous thromboembolism after orthopedic 
surgery, such as total hip or knee replacement, and the 
prevention of stroke and systemic arterial embolism in 
high-risk patients with non-valvular atrial fibrillation 
(1,2,11,12,18). 
A meta-analysis conducted in 2012 by Miller et al. (20) 
on the efficacy and safety of new anticoagulants (dab-
igatran, rivaroxaban, apaxiban) versus warfarin in pa-
tients with atrial fibrillation, found that new anticoagu-
lants are more effective than warfarin for the prevention 
of stroke and systemic embolism in patients with atrial 
fibrillation. Also they noted that intracranial hemor-
rhage risk is less, and therefore, have a higher safety 
than warfarin. Nevertheless, Healy et al. (7) have de-
termined that dabigatran has an increased risk of bleed-
ing when the patient is subjected to an urgent surgical 
procedure; in non-urgent cases, the risk of bleeding is 
similar in both dabigratran and warfarin. 
Dabigatran is well tolerated in single and multiple doses 
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Author and year Withdrawal of dabigatran or not Prior measures Subsequent measures 
Little et al. (9) 2012  No withdrawal  Consult with patient´s 
healthcare physician. 
Local measures 
Firriolo and Hupp 
(10) 2012  
No discontinue if low risk of bleeding and normal 
renal function.  
 
Discontinue use 24 hours prior if there is high risk 
of bleeding   
 
Discontinue use 1-5 days prior depending on 
renal function 
Resume use 24-48h after 
Tests: TT and aPTT 
Consult with patient´s 
physician. 
Cautious prescription of 
NSAIDs, opioid analgesics 
and macrolides.  
Sutures, gelatin or cellulose 
sponges tranexamic acid. 
Weitz et al. (12) 
2012 
No withdrawal. Perform cleanings or extractions 
10 hours after last dose  
  
Van Diermen et al. 
(13) 2013 
No withdrawal for simple procedures (up to 3 
extractions, 3 implants, scaling and root planning, 
flap surgeries, apicectomies and alveoloplasties) 
Consult with patient´s 
healthcare physician. 
Local measures: minimize 
trauma, suture wounds, local 
pressure, local hemostatics. 
Coehn et al. (5) 2013 Minor periodontal surgery or less than 3 
extractions: do not withdraw. 
Mayor surgery or more than 3 extractions: 
remove 48 hours prior to and resume 24 hours 
after procedure (normal renal function). 
Detailed medical history. 
Consult with patient´s 
physician. 
Sutures, gelatin hemostatic 
sponges. 
Davis et al. (11) 
2013 
Do not discontinue if low risk of bleeding and 
normal renal function.  
 
Discontinue use 24 hours before if high risk of 
bleeding.  
Discontinue 1-5 days before according to renal 
function  
Resume 24-48 hours after 
Tests: TT and aPTT 
Consult with patient´s 
healthcare physician  
Sutures, gelatin or cellulose 
hemostatic sponges,  
Sutures, gelatin or cellulose 
hemostatic sponges, 
mouthrinse with 5% 
tranexamic acid. 
Kerr et al. (14) 2013 No Consult with patient´s 
physician. 
Suture, local compression 
and hemostatics. 
Romond et al. (15) 
2013 
Discontinue 24 hours before if there is high risk 
of bleeding 
 Sutures, local hemostatics 
and compression, local 
anesthesia with 
vasoconstriction  
Breik et al. (16) 2014  Do not discontinue in cleanings, root canals, 
fillings with matrices or extractions of one tooth. 
Multiple extractions: assess withdrawal 24 hours 
before. 
Resume 24-48 hours after  
 
Tests: TT and aPTT 
Consult with patient´s 
physician 
Mechanical pressure, sutures 
and local hemostatic 
Curtin et al. (17) 
2014  
Surgeries with low risk of bleeding: do not 
withdraw. If withdrawal, monitor renal function 
and consult with patient´s physician.  
Consult with patient´s 
physician 
Mouthrinses with tranexamic 
acid 
Sivolella et al. (18) 
2015 
Do not withdraw if low risk of bleeding and 
normal renal function.. 
Discontinue use 24 hours before if high risk of 
bleeding.  
Discontinue use 1-5 days before according to 
renal function. 
Resume 24-48h after 
Consult with patient´s 
physician 
Local measures 
Gómez-Moreno et al. 
(8) 2015 
There are no recommendations Consult with patient´s 
physician 
Local measures 
 
Table 3.  Summary of papers regarding patients taking dabigatran who are undergoing dental procedures that cause bleeding.
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without occurrence of serious adverse effects. Minor 
adverse reactions include headache, gastrointestinal 
disturbances, peripheral edema, back pain, arthralgia, 
nasopharyngitis and insomnia (3,11). There is a high 
incidence of dyspepsia, gastritis-like symptoms, and 
hypersensitivity reactions (4,9).
Dabigatran has few interactions that are relevant from a 
clinical point of view. Rifampicin reduces the anticoagu-
lant effect of dabigatran, and as can also do other inducers 
of P-glycoprotein such as dexamethasone and carbam-
azepine. Inhibitors of P-glycoprotein as ketoconazole, 
itraconazole, erythromycin, clarithromycin, verapamil 
and amiodarone tend to increase the anticoagulant ef-
fect. Its use with other anticoagulants, antiplatelet agents, 
NSAIDs, salicylates and certain herbs (alfalfa, anise...) 
do not pose an interaction, but they can increase the risk 
of bleeding, and therefore, should be avoided. Drugs that 
can be used to control pain in patients taking dabigatran 
are opioids or acetaminophen (9-11).
In conclusion, we can add that the advantages of dabiga-
tran are speed of action, the wide therapeutic window, 
the low potential to cause interactions with other drugs 
or foods, and predictable anticoagulant effect, which 
eliminates the need for routine patient monitoring and 
management of the drug in fixed-doses (18). 
On the other hand, its disadvantages include the patient 
in treatment with dabigatran should comply strictly with 
taking scheduled doses (4,9). In addition, there is a high 
incidence of dyspepsia, gastritis-like symptoms and hy-
persensitivity (urticaria, rush, pruritus and anaphylactic 
shock) (4,8). It has also been seen, when compared with 
warfarin, the bleeding risk is greater when the patient 
undergoes a surgical procedure (7). In cases of major 
bleeding, there is no antidote to reverse the anticoagu-
lant effect (4,9); although some researchers have recent-
ly identified a possible antidote, an antibody fragment a 
Dabi-Fab, which directly neutralizes dabigatran (21).
- Management of patients anticoagulated with dabiga-
tran prior to dental procedures that involve bleeding.
There is no consensus regarding how to manage a pa-
tient medicated with dabigatran who needs to undergo 
a surgical procedure. However, all authors agree that 
we should individualize each case taking into consider-
ation the risk of bleeding during surgery, along with the 
risk of embolism (if we discontinue the medication) and 
renal function of the patient.
Healey et al. (7) in 2012 conducted a randomized clini-
cal trial which compared the risk of bleeding after sur-
gical procedures (including oral surgery as well) in pa-
tients taking dabigatran and patients taking warfarin, 
and came to the conclusion that bleeding complications 
are similar in both cases. Authors like Golembiewski 
advise that dabigatran should be discontinued before 
any surgical procedure that could have a bleeding risk. 
Drug withdrawal time is dependent on such bleeding 
risk, (standard or high) and renal function of the patient 
(4).
Unlike what happens with antiplatelet and anticoagu-
lants such as warfarin or acenocoumarol, for which there 
are clear guidelines for action on withdrawing or not the 
medication, as well as pre and postoperative measures 
taken with patients in the dental practice (5,13); nowa-
days there are recommendations for dabigatran based 
only on the pharmacological properties of the drug, 
and on experiences with isolated case reports or small 
groups of patients.
Almost all of the studies reviewed focus on patient 
management during extractions, with no papers and no 
specific recommendations for other oral treatments that 
produce bleeding, such as dental cleanings or scaling 
and root planning.
In cases in which minor bleeding occurs after surgery, 
it is recommended to postpone the next dose of the drug 
and adopt local measures. If bleeding is severe, treat-
ments available at the hospital level include mechanical 
compression, surgical interventions, fluid replacement, 
hemodynamic support, intake of activated carbon and 
hemodialysis (2).
In view of this systematic review, in which we have 
found no reliable clinical data derived from clinical tri-
als and general recommendations for the management 
of these patients in the dental office, we could include 
the following recommendations (Table 4):
Always perform a thorough medical history, in which 
both the dose and the cause of drug intake are noted. It 
must include diseases related to coagulation disorders, 
such as liver disease. Before any procedure in which we 
anticipate bleeding, one should consult with the patient s´ 
physician to develop a joint plan of action. This plan 
could include coagulation testing; it seems that the most 
appropriate and accessible tests in the case of dabiga-
tran are TT and aPTT.
To decide whether or not to withdraw the drug before 
surgery, one must assess the risk of bleeding from the 
dental treatment and the patient s´ renal function. De-
pending on the type of treatment to be performed, the 
practitioner must consider certain variables to establish 
the risk of bleeding. When extracting teeth, one will 
have to assess the number of teeth, the difficulty of the 
extractions, and the need for flaps. In case of implants, 
the number of implants to be placed will be assessed, if 
they are going to be placed in the maxilla or mandible 
(as the risk of bleeding will be different), and the need 
for muco-periosteal detachment. In periodontal therapy 
one should assess gingival inflammation, plaque index 
(PI) and pocket probing depth (PPD). If it is necessary 
to biopsy soft tissue, one should consider the anatomi-
cal area from which the sample is going to be taken, 
the size of the tissue to be removed, and whether or not 
suturing the area. As for restorative dentistry, if neces-
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sary to perform any subgingival restoration, it would 
be advisable to reduce gingival inflammation prior to 
restoration to lessen the risk of bleeding. 
As discussed in other papers, it is necessary to perform 
a procedure as atraumatic as possible and after surgery, 
local measures such as the use of sutures, gelatin or cel-
lulose sponges, tranexamic acid rinses and local pres-
sure should be applied.
As for prescription medication, one should be cau-
tious with opioid analgesics and macrolides; and azole 
antifungals are contraindicated. Overall, one should 
prescribe paracetamol as analgesic, and should avoid 
aspirin and NSAIDs; therefore, if post-surgical inflam-
mation is anticipated, the use of locally injectable ste-
roids should be assessed; and if great post-operative 
pain is expected, acetaminophen associated with co-
deine can be prescribed, always in moderation, since it 
is an opioid analgesic.
We believe appropriate to check on the patient within 
24 hours of the surgical procedure, and always provide 
a contact number in case excessive bleeding occurs, as 
well as a referral to an emergency hospital to attend if 
necessary.
In conclusion, dabigatran is a drug that is a viable al-
ternative to warfarin in the prophylactic treatment of 
stroke and systemic embolism in patients with atrial 
fibrillation. Therefore, we must take this into account 
when performing surgical and periodontal procedures 
to avoid the risk of postoperative bleeding, as well as, 
assess potential drug interactions with other drugs com-
monly used in dentistry. Although there are no well-de-
signed clinical studies yet, existing studies agree to treat 
each patient taking dabigatran in an individual manner. 
It will be important to consider the risk of embolism and 
postoperative bleeding, and renal function of the pa-
tient. All procedures should be as minimally invasive as 
possible and appropriate local anti-hemolytic measures 
should be taken. However, more properly designed stud-
ies should be designed to determine a common protocol 
for treating these patients, just as we have for patients 
treated with warfarin or acenocoumarol. 
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